Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ImmunoGen Inc | NASDAQ:IMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 31.235 | 32.80 | 29.67 | 0 | 00:00:00 |
From Nov 2023 to Nov 2024
By Colin Kellaher
Immunogen has won U.S. Food and Drug Administration priority review for its application seeking to convert the accelerated approval of its cancer therapy Elahere to full approval.
The Waltham, Mass., pharmaceutical company on Tuesday said the FDA has set a target action date of April 5, 2024, for the application.
In November 2022, the FDA granted accelerated approval to Elahere for the treatment of patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Elahere is the key asset in AbbVie's recent agreement to buy Immunogen for $10.1 billion.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 05, 2023 07:31 ET (12:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year ImmunoGen Chart |
1 Month ImmunoGen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
